Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s share price reached a new 52-week low on Wednesday . The stock traded as low as GBX 120 ($1.49) and last traded at GBX 120 ($1.49), with a volume of 38147 shares changing hands. The stock had previously closed at GBX 125 ($1.56).
Faron Pharmaceuticals Oy Stock Performance
The stock has a market capitalization of £81.37 million, a P/E ratio of -269.05 and a beta of -0.14. The company has a debt-to-equity ratio of 121.51, a quick ratio of 1.09 and a current ratio of 0.59. The company’s fifty day simple moving average is GBX 155.30 and its two-hundred day simple moving average is GBX 244.45.
Faron Pharmaceuticals Oy Company Profile
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
Recommended Stories
- Five stocks we like better than Faron Pharmaceuticals Oy
- Consumer Discretionary Stocks Explained
- Comprehensive Analysis of PayPal Stock
- What is a Death Cross in Stocks?
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Do ETFs Pay Dividends? What You Need to Know
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.